Back
OneSkin closes $7M Series A, accelerating groundbreaking efforts in skin health and longevity
Back
Ned Desmond
Ned Desmond

Skin health and longevity pioneers OneSkin, an alum of SOSV’s IndieBio SF from 2016, have closed their Series A, bringing total funding to date to $20M. Led by Selva Ventures alongside PLUS Capital, Unilever Ventures, SOSV and others, the raise empowers the brand to enter a new phase of growth and innovation in skin health.   

As reported in StreetInsider and WWD, OneSkin is a first-to-market category leader in science-led topical skin longevity treatments, whose patented ingredient, OS-01, is the first peptide scientifically proven to reverse skin’s biological age by preventing the accumulation of senescent cells. 

The startup landed on Fast Company’s list of Most Innovative Companies of 2024. Loyal users include Alana Hadid, Georgia May Jagger, Katy Perry, and more than a few SOSV employees. 

OneSkin was founded by four female Brazilian scientists. Commenting on the $7M in new funding, OneSkin Co-Founder and CEO Carolina Oliveira said the funding will “drive our mission to transform how we think about our skin, not only by optimizing our aesthetics using cutting-edge science, but also focusing on its functional role as our largest organ and the impact in our overall health and longevity.”

From their early days in the lab at IndieBio, to the discovery of OS-1, to taking the world of skin health and longevity by storm, OneSkin’s journey has been exhilarating to witness and support. With OS-1 already expanding skin’s health and lifespan, we (and our skin) can’t wait to see what they’ll do next! 

Did you know?